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SUMMARY 
Baclofen has been found to bind to receptors in the 
central nervous system that are specific for 7-aminobutyric 
acid (GABA), a well known inhibitory neurotransmitter. This 
paper describes the synthesis of a radioiodinated analog of 
baclofen as part of an effort to develop receptor probes 
useful in single photon emission computed tomography. 
Prel imi nary biodis tr ibut ion studies showed the 
radioiodinationed analog to be essentially stable to in vivo 
deiodination and have a distribution profile similar to that 
of baclof en. 
Keywords: GABA, Baclofen, Radioiodination, Radioiodinated 
baclofen analog 
INTRODUCTION 
7-Aminobutyric acid (GABA) is the major inhibitory 
neurotransmitter in the central nervous system (L). Two 
types of GABA receptors have been characterized and 
designated as GABAA and GABAB (2.3). These receptors are 
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selectively activated by muscimol (I) and baclofen, 
respectively. 
In contrast to GABA, muscimol (1) and baclofen can 
penetrate the blood brain barrier, although to a limited 
X 
Muscimol (1) X=Cl=Baclofen 
X=I= (l3) 
extent. This property was an important consideration in our 
goal to design a radiodiagnostic that could delineate the 
binding sites for GABA agonists in the central nervous 
system by single photon emission computed tomography 
(SPECT). Moreover, since iodine-123 is an ideal nuclide for 
SPECT studies, the replacement of the chlorine in baclofen 
with an iodine ( g )  seemed an attractive starting point. The 
greater lipophilicity of an iodine over chlorine substituent 
was also an advantage. Thus, the purpose of this study was 
to devise a route for the synthesis of g ,  label it with 
radioiodine and conduct a preliminary study to determine its 
biodistribution pattern similarity with baclofen and to 
ascertain its in vivo stability towards deiodination. 
CHEMISTRY 
Synthesis of the 4-iodo analog of baclofen, A_ was 
accomplished via a synthetic route starting from p- 
nitrobenzaldehyde as outlined in Scheme I. A Knoevenagel 
condensation between p-nitrobenzaldehyde and diethyl 
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malonate (4) in the presence of catalytic amounts of p- 
toluenesulfonic acid and piperidine (5) gave p- 
nitrobenzalmalonic acid diethyl ester 2 in an excellent 
yield. Introduction of a cyano group at the benzylic 
position of 2 via a Michael addition of cyanide was achieved 
by employing acetone cyanohydrin as the cyanide source under 
basic conditions, bringing about high yield of diethyl 
cyano(p-nitropheny1)methyl-malonate 3. Our first attempt to 
introduce a cyano group into 2 using potassium cyanide (6) 
was unsuccessful, the reaction gave a tarry mixture probably 
due to polymeric decomposition of the initial product 2 
under strongly alkaline conditions. Reduction of the 
aromatic nitro group in 3 with zinc powder and CaC12 in 78% 
EtOH (7) afforded the corresponding amino compound, diethyl 
p-aminophenyl(cyano)methyl malonate 5 in essentially 
quantitative yield, with the cyano group at the benzylic 
position remaining unaffected. Reduction of the benzylic 
cyano group was achieved by employing the NaBH -CoCl 
reagent system (8), whereby successive reduction and 
cyclization took place to give ethyl 2-oxo-4-(4- 
aminophenyl)-3-pyrrolidinecarboyxlate 3. We also examined 
the reduction of cyano and/or nitro groups on 2 or 4 
utilizing catalytic hydrogenation with PtOq, Pd/C or Raney 
nickel under atmospheric pressure of H2. 
reaction was sluggish and gave a complex mixture of products 
and starting material. Conversion of 5 to 4-(4- 
aminophenyl)-2-pyrrolidinone S was achieved by alkaline 
hydrolysis of the ester group followed by decarboxylation in 
mesitylene. The conversion of 5 to 4-(4-iodophenyl)-Z- 
pyrrolidinone 1 was done by first converting S to the 
corresponding diazonium salt and the diazonium group 
subsequently displaced by iodide. The synthesis of iodo- 
2 4 
In each case, the 
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baclofen, 3-(4-iodophenyl)-4-aminobutyric acid hydrochloride 
- 8, was achieved by heating the lactam 7- to reflux in 6N HC1 
for 3.5 hours. The synthesis of the [1251] iodinated 
baclofen analog, 9 was completed by exchange radiolabeling 
of 8 in an aqueous solution containing Na1251 in the 
Presence Of catalytic C U S o 4 ,  and the reductants SnS04 and 
ascorbic acid according to the procedure of Mertens et al. 
(9). 
Scheme 1 
4 
NOz 
Zn, CaC12 - 
78% EtOH 
1) NaNOz, HCI -
2) KI 
6 ‘OZEt (CH&C(CN)OH K2C03 N c $ - E L 0 2 E t  - 
THF:EtOH/l :1 
COpEt ’) NaoH 
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I 
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NalZ51, H20 
-
I 
- 7 8 - 9
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BIODISTRIBUTION RESULTS 
3 Biodistribution studies of 9 and [ HI baclofen are shown 
on Table I. Similar patterns of tissue uptake and renal 
clearance were observed for both compounds. At no time 
point was the brain/blood ratio greater than one in either 
case. Moreover, the iododinated baclofen analog showed 
little in vivo deiodination which may be the result of its 
inherent chemical stability along with its rapid clearance. 
Interestingly, racemic 2 showed a slightly greater 
accumulation in brain tissue at early time points when 
compared to ( - )  baclofen. Since GABA agonist action has 
been shown to be highly stereoselective for ( - )  baclofen 
(2), future studies require a) enantiomeric resolution of 2, 
b) assessment of each enantiomers affinity for the GABA 
receptors and c) eventual preparation of radioiodinated ( - 1  
9 in high specific activity. 
B 
TABLE I 
Radioactivity of various organs expressed as percent of 
administered dose per gram of tissue 
Minutes after administration 
TISSUE 1 3 5 10 15 30 60 
COMPOUND 9 
BLOOD 2.33 1.51 1.11 0.65 0.52 0.44 0.23 
BRAIN 0.11 0.06 0.07 0.05 0.05 0.05 0.03 
HEART 0.63 0.52 0.39 0.26 0.24 0.29 0.20 
KIDNEY 6.26 11.06 10.22 11.65 7.09 9.83 2.84 
LIVER 1.62 2.06 1.52 1.02 0.82 0.71 0.32 
THYROID 0.87 0.55 0.54 0.35 0.38 0.53 1.21 
L3H] BACLOFEN 
BLOOD 1.67 1.35 1.11 0.73 0.46 0.45 0.16 
BRAIN 0.03 0.04 0.04 0.03 0.03 0.03 0.02 
HEART 0.50 0.39 0.33 0.26 0.20 0.24 0.16 
KIDNEY 6.50 13.84 14.92 6.26 3.58 3.98 1.47 
LIVER 1.05 1.17 1.12 1.11 0.80 0.88 0.19 
THYROID 0.40 0.40 0.48 0.24 0.20 0.36 0.06 
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EXPERIMENTAL 
MATERIALS AND METHODS: 
Melting points are uncorrected and were measured with 
either a Yanagimoto micro melting point apparatus or a 
1 Thomas-Hoover apparatus. Proton magnetic resonance ( H NMR) 
spectra were obtained on either a JEOL PS-100 or Bruker 
WP27OSY instrument using Me4Si as an internal standard. 
Infared (IR) spectra were obtained on either a JASCO IRA-1 
or a Perkin-Elmer 281 spectrometer. Radiochromatograms of 
thin layer chromatography plates were obtained on a Vangard 
930 autoscanner. The HPLC system consisted of an Altex llOA 
pump, Excalibur 5 p n  (4.6 x 250 mm) C18 reverse phase 
column, Gilson 111 UV monitor (254 nm) and an in-line Bicron 
Analyst (Bicron Electronic Products, Newbury, Ohio) survey 
meter with a model GlLE low energy gamma scintillation probe 
and strip chart output. Elemental analysis was performed by 
either the Service Center of the Elementary Analysis of 
Organic Compounds, Kyushu University, or Midwest Microlabs 
Ltd., Indianapolis, IN. Column chromatography was performed 
on silica gel (70-230 mesh, Merck) . The 12’1 used was a no- 
carrier-added solution of Na12% (100 mCi/ml) in reductant- 
free dilute NaOH (pH 7-11) obtained from The Amersham 
Corporation, Arlington Hts., I L .  [ HI-(-)-Baclofen (sp. 
act. = 39.8 Ci/mmol) was purchased from Dupont NEN Research 
Products, Boston, MA. Tetrahydrofuran (THF) was distilled 
from LiAlH4 under argon just prior to use. 
solvents were of commercial grade and were used without 
further purification. All organic or inorganic reagents 
were purchased from commercial sources and used directly. 
3 
All other 
Diethyl 4-nitrobenzalmalonate (2): A solution of p- 
nitro-benzaldehyde (50g. 0.33 mole), diethyl malonate (53 g. 
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0.33 mole), piperidine (5.64 g. 0.066 mole) and p- 
toluenesulfonic acid monohydrate (6.3 g -  0.033 mole) in 
benzene (700 ml) was heated to reflux and the generated 
water removed with the aid of a Dean-Stark trap. When the 
reaction was complete (ca. 20h), the reaction mixture was 
allowed to cool to room temperature and benzene (200 ml) was 
added. The benzene solution was transferred to a separatory 
funnel, washed successively with water (twice), saturated 
sodium bicarbonate, and brine. The organic phase was dried 
over sodium sulfate and concentrated to dryness under 
reduced pressure. The resulting solid was recrystallized 
from ethanol to give 84.3 g (87%) of 2 as slightly greenish- 
yellow needles, m.p. 91-92OC. IR (nujol mull) 1725 cm-l 
(C=O ester); 'H-NMR (100 MHz, CDC13) 6 : 8.24 (d, J = 9 Hz, 
ZH, Aryl 3,5-H), 7.76 (s, lH, PhCH=), 7.60 (d, J = 9 Hz, 2H, 
Aryl 2,6-H), 4.35 (9, J = 7 HZ, 4H, COOCH2 x 2), 
= 7 Hz, 3H, CH3), 1.28 (t, J = 7 Hz, 3H, CH3). Analysis 
calculated f o r  CI4Hl5No6: C, 57.34; H, 5.16. Found: C, 
57.21; H, 4.97. 
1.35 (t, J 
Diethyl cyano(p-nitropheny1)methyl-malonate ( 3 ) :  To a 
stirred mixture of compound 2 (43.75 g. 0.149 mole) and 
acetone cyanohydrin (38.1 g, 0.448 mole ) in THF/EtOH (l:l, 
300 ml) was added dropwise a solution of potassium carbonate 
(3.94 g, 0.0067 mole) in 10 ml of water. The color of the 
reaction changed from pale yellow to purple and then turned 
to reddish orange at the end of the reaction. After the 
starting material had disappeared as indicated by TLC (30-45 
min.), the solution was acidified with 3N HC1 and the 
solvents evaporated under reduced pressure. The residual 
orange oil was dissolved in ether and the ether solution 
washed three times with water and dried over sodium sulfate. 
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Removal of the solvent under reduced pressure left an orange 
oil, which gradually solidified upon standing at room 
temperature. The solid obtained was filtered with the aid 
of a cold n-hexane/EtOH (l:l), washed with the same solvent, 
and dried under vacuum to give 39.1 g (81.8 % )  o f  almost 
pure cyanated product 3 as a pale yellow solid. 
Recrystallization from ethanol gave an analytically pure 
sample as pale yellow needles, m.p. 75-75OC. IR (nujol 
mull) 2250 (CN), 1760 and 1730 cm-l (C=O ester); 'H-NMR 
(100 MHz, CDCL3) 6 : 8.26 (d, J = 9 Hz, lH, Aryl 3,5-H), 
7.62 (d, J = 9 Hz, 2H, Aryl 2,6-H), 4.65 (d, J = 9 Hz, 1H 
ArCH), 4.25 (9, J = 7 Hz, 2H, COOCH,), 4.10 (q, J = 7 Hz, 
2H, COOCH2), 3.90 (d, J = 9 Hz, IH, CH(C02Et)2), 1.30 (t, J 
= 7 Hz, 3H, CH3), 1.16 (t, J = 7 Hz, 3H, CH3). Analysis 
calculated for C15H16N206: C, 56.25; H, 5.03. Found: C, 
56,22; H, 4.89. 
Diethyl p-aminophenyl(cyano)methylmalonate ( 4 ) :  To a 
stirred mixture of compound 2 (5.0 g, 15.6 mmole) and zinc 
powder (33.5 g) in 78% EtOH (110 ml) was added CaC12 (1.1 g) 
dissolved in water (1.5 ml). The brownish reaction mixture 
was immersed in a preheated oil bath and refluxed for 10 min 
(the color changed to almost colorless at the end of the 
reaction). The mixture was filtered through a Celite-pad 
and the filtered zinc was washed several times with hot 
ethanol. The filtrates were combined and evaporated under 
reduced pressure. The residual oil was dissolved in ether 
and the ether solution was washed (water and then brine), 
dried (Na SO4) and then evaporated to dryness to afford 
compound 5 (4.35 g, 96%) as a yellow oil. IR (neat) 3440, 
3340, and 3200 (NH2), 2240 (CN), 1750 and 1730 cm-l (C=O 
ester). This compound was subjected to next reaction 
without further purification. 
2 
A Radioiodinared Analogue of Baclofen I31 
Ethyl 2-oxo-4-(4-aminophenyl)-3-pyrrolidinecarboxylate 
(5): To a stirred solution of compound 2 (4.35 g, 15.0 
mmole) in methanol (80 m l )  was added CoC12A6H20 (6.75 g, 
28.4 mmole). The resulting dark purple solution was cooled 
in an ice bath and solid sodium borohydride (5.5 g ,  145.5 
mmole) was added over a period of 30 minutes (hydrogen gas 
evolved violently upon the addition of NaRH4 and a black 
solid precipitated). The ice bath was then removed and the 
reaction mixture stirred for 1 hour at room temperature. 3N 
HC1 (50 ml) was added to the reaction mixture and the 
mixture stirred until dissolution of the black precipitate 
occurred. Methanol was removed by distillation and the 
remaining aqueous mixture was transferred to a continuous 
extraction apparatus. After alkalinization with aqueous 
ammonia (insoluble cobalt complex precipitated), the mixture 
was extracted with ether (200 ml) fo r  24 hours. The solid 
obtained upon evaporation of the ether extract was washed 
with cold ether/ethanol (1O:l) and dried under vaccuum to 
give 1 .7  g (46%) of 3. as a pale yellow powder. 
Recystallization from ethanol gave an analytically pure 
sample, m.p. 149-150OC. IR (nujol mull) 3440, 3320 and 3190 
(ArNI12 and lactam NH), 1735 (C=O ester), and 1705 cm-' (C=O 
lactam ) ;  
Aryl 2,6-H), 6.95 (br s ,  lH, lactam NH) 6.60 (d, J = 8 Hz, 
2H, Aryl 3.5-H), 4.05-3.25 ( m ,  4H, lactam H's), 3.68 ( s ,  2H, 
Aryl NH2), 1.25 (t, J = 7 Hz, 3H, CH3). Analysis calculated 
for C13H16N203: C, 62.89; H, 6.50. Found: C, 63.10; H, 6.78. 
'H-NMR (100 MHz, CDCl,) 6 :  7.05 (d, J = 8 Hz, 2H, 
4-(4-Aminophenyl)-2-pyrrolidinone ( 6 ) :  Compound 5 (4.35 
g, 17.5 mmole) was dissolved in (10 m l )  hot ethanol. To 
this solution, aqueous 10M NaOH (2 ml) was added and the 
white solid (sodium salt) which formed was collected by 
filtration. The residue was washed with a small amount of 
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absolute ethanol, subsequently dissolved in water (15 ml) 
and treated with a calculated amount of hydrochloric acid 
(5.8 ml of 3N HCI). The resulting white solid (free acid) 
was collected by filtration, washed successively with water, 
ethanol and ether and then dried under vacuum. The product 
was suspended in mesitylene (15 ml) and the mixture was 
heated at 165-179 *C in an oil bath under a gentle stream of 
argon until decarboxylation was complete (the suspension 
changes to two-phase solution at the end of the reaction). 
After cooling, the solidified material was separated from 
the mixture, ground to a powder, washed with benzene, and 
dried under vacuum to give 2.5 g (81%) of 6 .  
Recystallization from ethanol gave an analytically pure 
sample, m.p. 154-155OC. IR (nujol mull) 3340, 3280, and 
3200 (Aryl NH2 and lactam NH), 1680 cm-' (C=O lactam); 
NMR (100 MHz,  DMSO-d6 + D20) 6 : 6.96 (d, J = 9 Hz, ZH, Aryl 
2,6-H), 6.36 (d, J = 9 Hz, 2H, Aryl 3.5-H), 3.64-3.26 (m, 
2H, CHZNHCO), 3.24-2.96 (m, 1H. ArCH), 2.60-2.05 (AB of ABX 
'H- 
system, = 2.46, aB = 2.16, JAB = 16 Hz, JAx = 9 Hz, JBx - 
9 Hz, 2H, CH2CONH). Analysis calculated for 
Cl0HI2N2O: C, 68.16; H, 6.86. Found: C, 68,39: H.6.71. 
4-(4-Iodophenyl)-2-pyrrolidinone (I): To an ice bath- 
cooled solution of compound 5 (0.5 g, 2.84 mmole) in 3N HC1 
(5 ml) was added sodium nitrite (0.216 g, 3.13 mmole) 
dissolved in water (1.0 ml). After stirring for 20 minutes, 
potassium iodide (0.566 g, 3.41 mmole) dissolved in water (5 
ml) was added and the reaction mixture stirred for ten 
minutes. The ice bath was then removed and the mixture was 
heated in an oil bath at 70-8O0C until evolution of N2 gas 
ceased. After cooling, the reaction mixture was extracted 
three times with chloroform. The chloroform extracts were 
combined and washed successively with saturated sodium 
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bicarbonate, aqueous sodium thiosulfate, water and brine. 
The washed extracts were dried over sodium sulfate and 
evaporated to dryness under reduced pressure. The crude 
product was purified by column chromatography on silica gel. 
Elution with CHC13/MeOH (50:l) gave 0.37 g (45.4%) of as a 
pale yellow solid. Analytically pure material was obtained 
by recrystallization from benzene, m.p. 143-145' C. IR 
(nujol mull) 3160 and 3080 (NH), 1720 cm-' (C=O lactam); 
'H-NMR (100 MHz, CDC13) 6 : 7.68 (d, J = 8 Hz, 2H, Aryl 3,5- 
H), 7.02 (d, J = 8 Hz, 2H, Aryl 2,6-H), 6.53 (br, lH, NH), 
3.90-3.50 (m, 2H, CH2CONH), 3.50-3.25 (m, lH, ArCH), 2.90- 
2.28 (AB of ABX system, 6A = 2.72, tiB = 2.42, JAB = 16 Hz, 
JAx = 8 Hz, 2H, CH2CONH). Analysis calculated for 
CIOHIOINO: C, 41.84; H, 3.51. Found: C, 42.21: H, 3.72. 
3-(4-Iodophenyl)-4-aminobutyric Acid Hydrochloride (8): 
Compound 1 (0.1 g, 0.348 mmole) suspended in 6N HC1 (10 ml), 
was heated at reflux under a stream of nitrogen for 3.5 hr. 
After cooling to room temperature, the solvent was 
completely removed by lyophilization to afford 0.118 g 
(100%) of almost pure g as a white powder. Recrystallization 
from EtOH/Et20 (2:l) gave analytically pure material (0.092 
g, 77%). m.p. 190-195OC (dec). 'H-NMR (270 MHz, DMSO-d6 + 
D 0) 6: 7.69 (d, J = 8.1 Hz, 2H, Aryl 3,5-H), 7.15 (d, J = 
8.2 Hz, 2H, Aryl 2,6-H), 3.33 (m, lH, ArCH), 3.13-2.91 (m, 
2 
2H. CH2NH2), 2.89-2.51 (AB of ABX system, 6A = 2.85, 6B = 
2.56, JAB = 16.3 Hz, JAx = 5.0 Hz, JBx = 9.5 Hz, 2H, 
CH2COOH). Analysis Calculated for C10H13C11N02: C, 35.16; 
H, 3-84; N, 4.10; I, 37.15 
4.22; I, 36.92. 
3-(4-[1251 J Iodophenyl 
Hydrochloride (3 ) :  To a 2. 
Found: C, 35.13; H, 3.66; N, 
-4-aminobutyric Acid 
0 ml crimp capped vial was added 
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- 8 (1.3 mg), SnS04 (0.5 mg), CuS04'5H20 (150 pg), ascorbic 
acid (6.0 mg) and oxygen free water (50 111). Following 
addition of an aqueous sodium iodide solution (5 p l ,  2.57 
M i ) ,  the vial was sealed, purged with nitrogen and heated 
to 100' C. After 30 minutes, the vial was cooled and the 
water removed under a gentle stream of N2. 
purified by silica gel column chromatography, eluted with 
CHC13:MeOH/1:1 followed by CHC13:MeOH:H 2 0/4:4:1. 
Radiochromatograms of the appropriate collected fractions 
indicated a pure product which co-migrated with 5 .  The 
product was isolated in a radiochemical yield of 1.74 mCi 
(67.1%). This corresponds to a specific activity of 
approximately 458 mCi/mmol. Rf = 0.51 in 
CHCl .MeOH:H20/4:4:1. 
The residue was 
3 '  
TISSUE DISTRIBUTION 
Tissue distribution studies were performed with female 
Sprague-Dawley rats from Charles River, Portage, MI. 
weighing 200-260 grams. One animal at each time point was 
used in these preliminary studies. All animals received a 
tracer dose of 7.2-11.1 pCi of the radiolabeled compounds in 
water by intravenous injection into the tail vein while 
under light ether anesthesia. The animals were then placed 
under general ether anesthesia and sacrificed at the 
indicated time points by exsanguination. Major organs were 
excised, blotted dry and disected free of connective tissue. 
Large organs were minced with scissors. Weighed samples 
containing radioiodine were placed in gelatin capsules and 
counted on a Searle 1185 well counter (efficiency = 84--86%). 
Weighed samples containing tritium were dissolved as 
previously described (10). 10 ml of Safety-solv cocktail 
(RPI, M. Prospect, I L )  added and counted on a Tracor 6881 
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liquid Scintillation counter. Radioactivity concentration 
in each organ was expressed as percent of administered dose 
per gram of tissue. 
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